Table 1. Description of the study population from a nested case-control study of acrylamide biomarkers and EOC in the EPIC cohort.
| All EOC cases n=334 | Invasive serous EOC cases n=191 | Controls n=417 | |
|---|---|---|---|
| HbAA pmol/g of Hb a | 42.2 (33.9-54.4) | 42.2 (33.8-56.6) | 43.1 (33.8-54.8) |
| HbGA pmol/g of Hb a | 37.0 (28.5-49.5) | 37.0 (28.1-52.2) | 35.4 (26.0-49.9) |
| HbAA+HbGA pmol/g of Hb a | 79.3 (62.5-105.4) | 82.1 (62.0-107.8) | 78.7 (60.6-106.0) |
| HbGA/HbAA pmol/g of Hb a | 0.9 (0.7-1.0) | 0.9 (0.7-1.0) | 0.8 (0.7-1.0) |
| Age at recruitment (y) a | 58.4 (53.8-63.4) | 57.7 (53.0-62.7) | 59.2 (54.4-64.2) |
| Age at first menstrual period (y) a | 13.0 (12.0-14.0) | 13.0 (12.0-14.0) | 13.0 (12.0-14.0) |
| Age at menopause (y) a | 49.5 (49.0-52.0) | 49.5 (49.0-51.0) | 49.5 (48.0-52.0) |
| BMI (Kg/m2) a | 26.4 (23.4-29.3) | 26.0 (22.8-29.3) | 25.8 (23.2-29.5) |
| Country b | |||
| France | 32(9.6) | 23 (12.0) | 30 (7.2) |
| Italy | 43 (12.9) | 25 (13.1) | 52 (12.5) |
| Spain | 36 (10.8) | 21 (11.0) | 55 (13.2) |
| United Kingdom | 71 (21.3) | 29 (15.2) | 94 (22.5) |
| The Netherlands | 59 (17.7) | 37 (19.4) | 78 (18.7) |
| Greece | 27 (8.1) | 10 (5.2) | 43 (10.3) |
| Germany | 45(13.5) | 33 (17.3) | 46 (11.0) |
| Sweden | 21 (6.3) | 13 (6.8) | 19 (4.6) |
| Fasting status b | |||
| Unknown | 3 (0.9) | 1 (0.5) | 2 (0.5) |
| <3 hours | 169 (50.6) | 97 (50.8) | 213 (51.1) |
| 3-6 hours | 44 (13.2) | 23 (12.0) | 58 (13.9) |
| >6 hours | 118 (35.3) | 70 (36.7) | 44 (34.5) |
| Alcohol consumption b | |||
| Non drinker | 80 (24.0) | 47 (24.6) | 93 (22.3) |
| >0-6 | 166 (49.7) | 95 (49.7) | 178 (42.7) |
| >6-12 | 35 (10.5) | 22 (11.5) | 73 (17.5) |
| >12-24 | 38 (11.4) | 19 (10.0) | 50 (12.0) |
| >24-60 | 15 (4.5) | 8 (4.2) | 23 (5.5) |
| Ever use of OC b | |||
| Unknown | 6 (1.8) | 3 (1.6) | 4 (1.0) |
| No | 209 (62.6) | 114 (59.7) | 239 (57.3) |
| Yes | 119 (35.6) | 74 (38.7) | 174 (41.7) |
| Ever use of HRTb | |||
| Unknown | 12 (3.6) | 8 (4.2) | 13 (3.1) |
| No | 229 (68.6) | 123 (64.4) | 325 (77.9) |
| Yes | 93 (27.8) | 60 (31.4) | 79 (18.9) |
| Parity b | |||
| Unknown | 41 (12.3) | 27 (14.1) | 58 (13.9) |
| 1 child | 129 (38.6) | 81 (42.4) | 161 (38.6) |
| 2 children | 99 (29.6) | 53 (27.8) | 141 (33.8) |
| >=3 children | 48 (14.4) | 23 (12.0) | 44 (10.6) |
| Nulliparous | 8 (2.4) | 4 (2.1) | 9 (2.2) |
| Parous but with missing number of full-term pregnancies | 9 (2.7) | 3 (1.6) | 4 (1.0) |
EOC, epithelial ovarian; EPIC, European Prospective Investigation into Cancer and Nutrition; HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide, BMI, body mass index; OC, oral contraceptive; HRT, hormone replacement therapy
a
Median and quartile range (25th – 75th percentile)
b
number (n) and percent (%)